**Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2**

Jian-Guo Qiao, Yu-Qing Zhang, Yu-Chun Yin, Zui Tan

**AIM:** To investigate the expression of Survivin in pancreatic cancer and its correlation to the expression of Bcl-2.

**METHODS:** Survivin and Bcl-2 expressions were examined by immunohistochemistry in 42 tissue samples from pancreatic cancer and 10 from normal pancreas.

**RESULTS:** No survivin expression was detected in the tissue samples from normal pancreas, while it was detected in 34 of 42 tissue samples from pancreatic cancer (81.95%). There was a correlation between survivin expression and differentiation and stages of pancreatic cancer. Survivin positive cases were strongly correlated to Bcl-2 expression (28/30 vs 6/12, P<0.05).

**CONCLUSION:** Overexpression of survivin plays an important role in the development and progression of pancreatic cancer, and correlates to the expression of Bcl-2. Survivin expression can be used as a prognostic factor.

Qiao JG, Zhang YQ, Yin YC, Tan Z. Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol 2004; 10(18): 2759-2761 http://www.wjgnet.com/1007-9327/10/2759.asp

**INTRODUCTION**

The inhibitor of apoptosis protein (IAP) is a member of the widely-expressed gene family of apoptosis inhibitors. It can inhibit apoptosis induced by a variety of stimuli and plays a critical role in the physiologic activities of cells. Survivin is a recently-characterized gene, a member of the IAP family, and has a close relation between anti-apoptosis and tumors. Overexpression of survivin has been reported to play an important role in the development and progression of pancreatic cancer[1-5]. In this study, we investigated the relationship between the expression of survivin in patients with pancreatic cancer and the expression of Bcl-2 in order to provide a theoretical basis for the prevention, diagnosis, and treatment of pancreatic cancer.

**MATERIALS AND METHODS**

**Materials**

Ten samples from normal pancreatic tissue and 42 samples from pancreatic cancer were collected. Normal pancreatic tissues were obtained from autopsy specimens in Department of Anatomy, Medical College, Wuhan University, and their mean age was 49.3 years (range, 33-78). Pancreatic cancer samples were obtained from surgically-resected specimens in Zhongnan Hospital, Wuhan University. All these cancers were diagnosed pathologically.

**Reagents**

Primary antibody for survivin was purchased from Novus Co., Ltd (USA) and Bcl-2 was purchased from Boster Biological Technology Ltd (Wuhan). SP kit was purchased from Zhongshan Biotechnology Co., Ltd (Beijing).

**Methods**

Fixed in routinely-processed formalin and then embedded in paraffin, 4-µm thick sections were prepared from the cut surface of blocks at the maximum cross-section. For morphological analysis, the sections were routinely stained with hematoxylin and eosin. Immunohistochemical staining for survivin and Bcl-2 antigen was made by the standard streptavidin/peroxidase (SP) technique. The positive section was used as a positive control. As a negative control, PBS was used instead of the primary antibody for survivin and Bcl-2.

**Scoring criteria**

Cytoplasm staining with light yellow or brown was defined as a marker of positive cells. All sections were analyzed by an image analysis system. The mean percentage of positive cells for the expression of survivin and Bcl-2 was determined in at least 10 areas at 400-fold magnification, and the cases with less than 5% positively-stained cells were defined as being negative. The cases with 5% to 10% positively-stained cells were defined as having a positivity rate of “+”, 11% to 60% as “++”, and more than 60% as “+++”.

**Statistical analysis**

All statistical analyses were performed with SPSS 11.0 software. Difference and correlation were analyzed by χ² test. P<0.05 was considered statistically significant.

**RESULTS**

**Immunohistochemistry**

With immunohistochemical staining, we examined the expression of survivin in pancreatic cancer. The results are shown in Figure 1. The expression of survivin was localized in cytoplasm of tumor cells, which are shown as brown granules in Figure 1 (SP), and in Figure 2 (HE). Survivin was expressed in 34 of 42 pancreatic cancer samples, but not expressed in the 10 samples from normal pancreatic tissue. The expression rate was 81.95%.

To study the relationship between the expressions of survivin and Bcl-2, 42 cases were analyzed. The results are shown in Table 2.
Survivin, a recently-characterized member of IAP family, was isolated from the human gene bank by Altieri et al. in 1997 using effector cell protease receptor-1 (EPR-1) cDNA. Recently, great progress has been made in the structure and function of survivin and its correlation to malignant tumors.

Many findings have suggested that survivin may express selectively in different tissues. Survivin was max expressed or poorly expressed in normal terminally-differentiated tissues, whereas it was extensively expressed in many kinds of human tumor tissues.

Studies have shown that Caspase is responsible for apoptosis, which can activate in cascade and lyse protein, thus determining the pattern of apoptosis. Survivin could directly inhibit the activities of Caspase-3 and 7 and block the process of apoptosis and indirectly inhibit Caspase through P21. Therefore, survivin would bind to cell cycle apoptosis factor CDK4 to form survivin-CDK4 complex, and then release of P21 from CDK4 complex. When P21 was bound to mitochondrial Caspase-3, it could inhibit its activity, thus preventing apoptosis.

The results of our study showed that survivin was highly expressed in pancreatic tumor tissues, but not in normal pancreatic tissues, suggesting that it might play a critical role in the development and progression of pancreatic cancer. Furthermore, there was a positive correlation between survivin expression and tumor TNM staging and differentiation grade. It can be concluded that survivin expression is indicative of higher invasiveness or poor prognosis in pancreatic cancer.

Bcl-2 was the first characterized anti-apoptotic gene with an inhibiting apoptotic pathway different from that of survivin. Bcl-2 could regulate apoptosis by preventing cytochrome C release from mitochondrion to cytoplasm. Whereas, survivin acted by direct inhibition of the terminal effector proteases of apoptosis, i.e., Caspase-3 and Caspase-7.

Our study demonstrated that the expression of survivin was positively correlated with that of Bcl-2. It might be caused by the same transcription and activation mechanism of survivin and Bcl-2, or both might be regulated by GC-rich promoters, and were then transcripted and activated to enhance cell proliferation, acting synergistically to inhibit apoptosis.

Asanuma et al. investigated whether survivin expression could directly regulate cancer sensitivity to radiotherapy using gene-transduced pancreatic cancer cell strain (MIA PaCa-2). Their results showed that survivin expression could directly down-regulate pancreatic cancer sensitivity to radiotherapy.

In addition, Rohayem et al. observed that specific anti-survivin antibody could be detected in serum of patients with cancers of the lung and colon, suggesting that this antibody could be used as a new diagnostic marker for cancers of the lung and colon. Furthermore, Smith et al. found that survivin levels in urine could be used to diagnose primary and recurrent bladder carcinomas, thus providing a new idea for the diagnosis of pancreatic cancer.

In conclusion, Survivin can be used as a cancer therapeutic target because of its selective expression in the tissue concerned. Moreover, natural antisense nucleic acid for Survivin-endogenous EPR-1 has become a new hot issue for the tumor gene therapy.

### REFERENCES

1. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. *Cancer* 2001; 92: 271-278

2. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N. A role for survivin in radio resistance of pancreatic tumor of the pancreas: special reference to the roles of Survivin. *Br J Cancer* 2002; 86: 886-892

3. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guilou P. Expression of Survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. *Br J Cancer* 2002; 86: 1057-1062

4. Jinfei M, Kimura W, Sakurai F, Moriya T, Takeshita A, Hirai H. Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT. *Int J Gastrointest Cancer*
Survivin and Bcl-2 in pancreatic cancer

Qiao JG et al. Survivin and Bcl-2 in pancreatic cancer

2002; 32: 73-81

5 Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radio resistance factor in pancreatic cancer. *Jpn J Cancer Res* 2000; 91: 1204-1209

6 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. *Nat Med* 1997; 3: 917-921

7 Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary Survivin levels and outcome. *J Urol* 2003; 170: 230-234

8 Altieri DC. Validating survivin as a cancer therapeutic target. *Nat Rev Cancer* 2003; 3: 46-54

9 Altieri DC. Survivin and apoptosis control. *Adv Cancer Res* 2003; 88: 31-52

10 Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. *Trends Mol Med* 2001; 7: 542-547

11 Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. *Blood* 2001; 97: 2784-2790

12 Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer. *Cancer Res* 1998; 58: 5071-5074

13 Lu CD, Altieri DC, Tanigawa N. Expression of a novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. *Cancer Res* 1998; 58: 1808-1812

14 Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognini S, Villa A, Marchisio PC, Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with Survivin function. *Nat Cell Biol* 1999; 1: 461-466

15 Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaka Y, Tsutomi Y, Akahane K, Nakano T, Miure M, Shiraki K. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with CDk4 to resist Fas-mediated cell death. *Oncogene* 2000; 19: 1346-1353

16 Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepato-cellular carcinoma. *Hepatology* 2000; 31: 1080-1085

17 Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bells C, Castano A, Díez A, Flores T, Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre MJ, Mollejo M, Sáez AI, Sánchez L, Piris MA. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. *Blood* 2003; 101: 681-689

18 Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Smittz M, Møhljorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein Survivin in cancer patients. *Cancer Res* 2000; 60: 1815-1817

19 Sharief MK, Semra YK. Down-regulation of Survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis. *Arch Neurol* 2002; 59: 1115-1121

20 Agui T, McConkey DJ, Tanigawa N. Comparative study of various biological parameters, including expression of Survivin, between primary and metastatic human colon adenocarcinomas. *Anticancer Res* 2002; 22: 1769-1776

21 Gradilone A, Gazzaniga P, Ribuddo D, Scarpa S, Cigna E, Vasaturo F, Bottuni O, Innocenti D, Calvieri S, Scuderi N, Frati L, Aglianò AM. Survivin, bcl-2, bax, and bcl-x gene expression in sentinel lymph nodes from melanoma patients. *J Clin Oncol* 2003; 21: 306-312

22 Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell-and serous-type ovarian carcinomas. *Int J Oncol* 2001; 19: 537-542

23 Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A. Expression of survivin and Bcl-2 in the normal human endometrium. *Mol Hum Reprod* 2000; 6: 529-534

24 Rodel F, Hoffman J, Grabenbauer GG, Papadopoulos T, Weiss C, Gänther K, Schick C, Sauer R, Rodel C. High Survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. *Strahlenther Onkol* 2002; 178: 426-435

25 Guan J, Chen J, Luo Y, Gao J, Qiu H. Effects of antisense bcl-2 or survivin on the growth of human neuroblastoma cell line SK-N-MC. *Zhonghua Yi Xue Za Zhi* 2002; 82: 1536-1540

26 Sarela AJ, Scott N, Ramsdale J, Markham AF, Guille PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. *Ann Surg Oncol* 2001; 8: 305-310

27 Hiroshima K, Iyoda A, Toyozaki T, Supriatna Y, Shibuya K, Shimamura F, Haga Y, Yoshida S, Fujisawa T, Ohwada H. Proliferative activity and apoptosis in thymic epithelial neoplasms. *Med Pathol* 2002; 15: 1326-1332

28 Mikami T, Yoshida T, Akino F, Motoori T, Yajima M, Okiyasu I. Apoptosis regulation differs between ulcerative colitis-associated and sporadic colorectal tumors. Association with Survivin and Bcl-2. *Am J Clin Pathol* 2003; 119: 723-730

29 Park JW, Choi YJ, Suh SI, Back WK, Suh MH, Jin IN, Min DS, Woo JH, Chang JS, Passaniti A, Lee YH, Kwon TK. Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. *Carcinogenesis* 2001; 22: 1653-1639

30 Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein Survivin in cancer patients. *Cancer Res* 2000; 60: 1815-1817

31 Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. *J Clin Oncol* 1999; 17: 2100-2104

32 Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of Survivin and diagnosis of bladder cancer. *JAMA* 2001; 285: 324-328

33 Moore M. Urine detection of Survivin and diagnosis of bladder cancer. *J Urol* 2001; 33: 202-203

34 Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the anti apoptosis molecule Survivin and recurrence of bladder cancer. *N Engl J Med* 1999; 341: 452-453

35 Yamamoto T, Tanigawa N. The role of Survivin as a new target of diagnosis and treatment in human cancer. *Med Electron Microsc* 2001; 34: 207-212

36 Sela B. Survivin: anti-apoptosis protein and a prognostic marker for tumor progression and recurrence. *Harefuh* 2002; 141: 103-107

37 Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by anti Survivin oligonucleotides. *Mol Cancer Ther* 2002; 1: 687-694

38 Carter BW, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. *Cell Cycle* 2003; 2: 488-493

39 Li F. Survivin study: what is the next wave? *J Cell Physiol* 2003; 197: 8-29